FDA Denies WLF Petition To Allow Dissemination Of Off-Label Information
This article was originally published in The Gray Sheet
Executive Summary
Dissemination of journal reprints representing off-label use of a device or drug will not by themselves trigger FDA enforcement action against a manufacturer, according to the agency